SCHEMBL6842068

SCHEMBL6842068

O=C1C=C(Nc2ccc(C(=O)c3ccc(NC4=CC(=O)NC4=O)cc3)cc2)C(=O)N1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 2/20 0.46
MAPK12 P53778 2/20 0.46
MAPK11 Q15759 2/20 0.46
MAPK14 Q16539 2/20 0.46
ADRA2A P08913 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
STK10 O94804 1/20 0.39
SLK Q9H2G2 1/20 0.39
DNM1 Q05193 1/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
ALDH1A1 P00352 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GSK3B P49841 1/20 0.35
TTBK1 Q5TCY1 2/20 0.34
TTBK2 Q6IQ55 2/20 0.34
KDM4E B2RXH2 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL87616 0.78 GSK3B (0.47) STK10SLKMEN1KMT2ANPC1
SCHEMBL8587478 0.72 KMT2A (0.46) MAPK13MAPK12MAPK11MAPK14KMT2A
SCHEMBL29393770 0.69 LMNA (0.37) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL22144431 0.69 NAMPT (0.41)
SCHEMBL29587864 0.66 ALDH1A1 (0.48) MAPK13MAPK12MAPK11MAPK14MEN1
SCHEMBL2742816 0.65 MAPK13 (0.95) MAPK13MAPK12MAPK11MAPK14MEN1
SCHEMBL29196087 0.65 MAPK13 (0.95) MAPK13MAPK12MAPK11MAPK14MEN1
SCHEMBL339890 0.64 RAB9A (0.49) MAPK13MAPK12MAPK11MAPK14MEN1
SCHEMBL5987355 0.64
SCHEMBL5154269 0.63 MAPK13 (1.00) MAPK13MAPK12MAPK11MAPK14MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6797841-B2 HAVING PHOTOINITIATION ACTIVITY WITH MINIMAL OR NO ADVERSE HAZARDOUS CHARACTERISTICS ALBEMARLE CORPORATION 2004-09-28 US claimed
US-6781015-B2 PHOTOPOLYMERIZATION ALBEMARLE CORPORATION 2004-08-24 US claimed
US-6762323-B2 EXPOSING A FORMUALTION CONTAINING A PIGMENT AND A PHOTOPOLYMERIZABLE COMPOUND HAVING AN ETHYLENICALLY UNSATURATED DOUBLE BOND TO RADIATION IN PRESENCE NON-MUTAGENIC PHOTOINITIATOR ALBEMARLE CORPORATION 2004-07-13 US claimed
US-20030078313-A1 Aminobenzophenones and photopolymerizable compositions including the same ALBEMARLE CORPORATION 2003-04-24 US claimed
US-20030073754-A1 Aminobenzophenones and photopolymerizable compositions including the same ALBEMARLE CORPORATION 2003-04-17 US claimed
US-20030065049-A1 Aminobenzophenones and photopolymerizable compositions including the same ALBEMARLE CORPORATION 2003-04-03 US claimed
US-6479706-B1 Aminobenzophenones and photopolymerizable compositions including the same ALBEMARLE CORPORATION 2002-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073754-A1 Aminobenzophenones and photopolymerizable compositions including the same TYR, AASDHPPT, ALAD MAPK13 2785/4885MAPK12 2826/4885MAPK11 2884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.